Hanihara and colleagues [26] reported a slight increase in the survival duration of mice given orthotopic intracranial GL261 cell tumours when they administered TMZ in combination with the weak IDO1 inhibitor 1-methyltryptophan (1-MT), compared to TMZ alone. Here, IDO1 is linked to neoplasm.